Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Adimab, Kite Pharma deal

    Adimab LLC, Lebanon, N.H. Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Business: Cancer, Antibodies Adimab will generate human IgG antibodies against undisclosed targets selected by Kite, which has the right to …

    Published on 6/29/2015
  • amp biosimilars deal

    amp biosimilars AG, Hamburg, Germany Business: Antibodies, Biosimilars amp granted an undisclosed Chinese pharma exclusive rights to commercialize ABY-021 in China. The humanized mAb is a biosimilar of an undisclosed …

    Published on 6/29/2015
  • Apexigen Inc., 3SBio deal

    Apexigen Inc., San Carlos, Calif. 3SBio Inc. (HKSE:1530), Shenyang, China Business: Autoimmune Apexigen granted 3SBio rights outside of China to SSS07. 3SBio already held rights in China to the humanized mAb that …

    Published on 6/29/2015
  • Bind Therapeutics, Navidea deal

    Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Navidea Biopharmaceuticals Inc. (NYSE-M:NAVB), Dublin, Ohio Business: Cancer Bind partnered non-exclusively with Navideas Macrophage Therapeutics subsidiary to …

    Published on 6/29/2015
  • BioInvent, University of Southampton deal

    BioInvent International AB (SSE:BINV), Lund, Sweden University of Southampton, Southampton, U.K. Business: Cancer BioInvent and the university partnered to develop antibodies targeting T regulatory cells to treat cancer…

    Published on 6/29/2015
  • bluebird bio, Kite Pharma deal

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Business: Cancer Kite and bluebird partnered to develop and commercialize second-generation T cell receptor (TCR) …

    Published on 6/29/2015
  • Cardiff University, Tiziana Life Sciences deal

    Cardiff University, Cardiff, U.K. Tiziana Life Sciences plc (LSE:TILS), London, U.K. Business: Cancer The university granted Tiziana exclusive, worldwide rights to small molecule OH14. Tiziana plans to develop the …

    Published on 6/29/2015
  • Cyclenium Pharma, McGill University deal

    Cyclenium Pharma Inc., Sherbrooke, Quebec McGill University, Montreal, Quebec Business: Cancer, Pharmaceuticals Cyclenium and McGill partnered to identify macrocyclic modulators. Cyclenium said the deal will focus on …

    Published on 6/29/2015
  • CytoSorbents, AlphaMedix deal

    CytoSorbents Corp. (NASDAQ:CTSO), Monmouth Junction, N.J. AlphaMedix Ltd., Petah Tikva, Israel Business: Cardiovascular CytoSorbents granted AlphaMedix exclusive rights to develop and commercialize CytoSorb for critical…

    Published on 6/29/2015
  • Dainippon Sumitomo, Takeda deal

    Dainippon Sumitomo Pharma Co. Ltd., Osaka, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Neurology The partners will terminate a 2011 deal granting Takeda exclusive rights to develop and …

    Published on 6/29/2015
  • Dynavax, Merck deal

    Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer The companies partnered to evaluate product combinations for clinical testing. Merck will sponsor…

    Published on 6/29/2015
  • GlaxoSmithKline, Altius Institute deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Altius Institute for Biomedical Sciences, Seattle, Wash. Business: Functional genomics GlaxoSmithKline signed a 10-year deal with Altius to research technologies and …

    Published on 6/29/2015
  • GlaxoSmithKline, Pfizer deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Infectious GlaxoSmithKline will sell quadrivalent meningitis vaccines Nimenrix and Mencevax to Pfizer for EUR115 …

    Published on 6/29/2015
  • IGXBio, Cannabis Science deal

    IGXBio Inc., Lenexa, Kan. Cannabis Science Inc. (OTCBB:CBIS), Colorado Springs, Colo. Business: Infectious The companies will combine Cannabis CS-TATI-1 with IGXBios GenePro to treat HIV infection. Cannabis will provide…

    Published on 6/29/2015
  • Johns Hopkins University, Bayer deal

    The Johns Hopkins University, Baltimore, Md. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Ophthalmic The university granted Bayers Bayer HealthCare LLC subsidiary an exclusive, worldwide option to IP from a five…

    Published on 6/29/2015
  • KineMed, Pronutria deal

    KineMed Inc., Emeryville, Calif. Pronutria Biosciences Inc., Cambridge, Mass. Business: Pharmaceuticals The companies partnered to use KineMeds proteomics technology to evaluate the physiological effects of Pronutrias …

    Published on 6/29/2015
  • OctreoPharm, Ipsen deal

    OctreoPharm Sciences GmbH, Berlin, Germany Ipsen Group (Euronext:IPN;Pink:IPSEY), Boulogne-Billancourt, France Business: Cancer Ipsen will acquire radiopharmaceutical company OctreoPharm for about EUR30 million ($34 …

    Published on 6/29/2015
  • Parion, Vertex deal

    Parion Sciences Inc., Durham, N.C. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Business: Pulmonary Parion granted Vertex exclusive, worldwide rights to a portfolio of epithelial sodium channel (ENaC) …

    Published on 6/29/2015
  • Prothena, The Michael J. Fox Foundation For Parkinsons Research deal

    Prothena Corp. plc (NASDAQ:PRTA), Dublin, Ireland The Michael J. Fox Foundation For Parkinsons Research, New York, N.Y. Business: Neurology Prothena and the foundation partnered to discover biomarkers and develop assays…

    Published on 6/29/2015
  • STC Biologics, Immune Pharmaceuticals deal

    STC Biologics Inc., Cambridge, Mass. Immune Pharmaceuticals Inc. (NASDAQ:IMNP;SSE:IMNP), New York, N.Y. Business: Cancer Immune and STC partnered to accelerate the development NanomAbs antibody-drug conjugates for …

    Published on 6/29/2015
  • Synageva, Alexion deal

    Synageva BioPharma Corp., Lexington, Mass. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Business: Endocrine/Metabolic Alexion completed its acquisition of Synageva for $115 in cash and 0.6581 Alexion …

    Published on 6/29/2015
  • Takeda, Sanford-Burnham Medical Research Institute deal

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Sanford-Burnham Medical Research Institute, La Jolla, Calif. Business: Cardiovascular Sanford-Burnham and Takeda partnered to study and develop compounds aimed …

    Published on 6/29/2015
  • Tesaro, Merck deal

    Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer The companies partnered to evaluate Tesaros niraparib (MK-4827) in combination with Mercks melanoma drug Keytruda …

    Published on 6/29/2015
  • Tribute Pharmaceuticals, Pozen deal

    Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF;TSX-V:TRX), Milton, Ontario Pozen Inc. (NASDAQ:POZN), Chapel Hill, N.C. Business: Autoimmune, Neurology, Cardiovascular Pozen is acquiring fellow specialty pharma Tribute…

    Published on 6/29/2015
  • University of Minnesota, Abeona Therapeutics deal

    University of Minnesota, Minneapolis, Minn. Abeona Therapeutics Inc. (NASDAQ:ABEO), Dallas, Texas Business: Hematology The university granted Abeona exclusive, worldwide rights to CRISPR-Cas9 gene editing technology and…

    Published on 6/29/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993